J. Burns

P. Cosson, J. Burns, C. van Delden, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

No evidence for chromosomal mosaicism in multiple tissues of 10 patients with 45 XO Turner syndrome

J. Callis, H. Hoehn, J. Burns, 1979, Clinical genetics.

Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa

A. Smith, J. Burns, G. Morlin, 1994, Journal of clinical microbiology.

Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings.

David J Weber, L. Saiman, N. Høiby, 2000, American journal of infection control.

Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.

Samuel I. Miller, J. Emerson, B. Ramsey, 2007, The Journal of infectious diseases.

Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia

J. Burns, D. M. Lien, L. Hedin, 1989, Antimicrobial Agents and Chemotherapy.

Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability

J. Burns, D. M. Lien, L. Hedin, 1989, Antimicrobial Agents and Chemotherapy.

Effect of tobramycin on protein synthesis in 2-deoxystreptamine aminoglycoside-resistant clinical isolates of Haemophilus influenzae

A. Smith, J. Burns, J. Levy, 1986, Antimicrobial Agents and Chemotherapy.

Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota.

L. Hoffman, R. Gibson, S. Mcnamara, 2014, Annals of the American Thoracic Society.

Cloning and expression in Escherichia coli of a gene encoding nonenzymatic chloramphenicol resistance from Pseudomonas aeruginosa

C. Rubens, A. Smith, J. Burns, 1986, Antimicrobial Agents and Chemotherapy.

Patients Isolates from Cystic Fibrosis aeruginosa Pseudomonas Susceptibility Testing of Methodologies for Antimicrobial Comparison of Agar Diffusion

Ronald N. Jones, L. Saiman, J. Burns, 2000 .

A major outer-membrane protein functions as a porin in Haemophilus influenzae.

A. Smith, J. Burns, A. Smith, 1987, Journal of general microbiology.

Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

J. Emerson, R. Gibson, B. Ramsey, 2009, The Journal of pediatrics.

Engineered Cationic Antimicrobial Peptides To Overcome Multidrug Resistance by ESKAPE Pathogens

R. Montelaro, J. Burns, B. Deslouches, 2014, Antimicrobial Agents and Chemotherapy.

Engineered Cationic Antimicrobial Peptides ( eCAPs ) to Overcome Multidrug Resistance by 1 ESKAPE Pathogens 2

J. Burns, B. Deslouches, Y. Doi, 2014 .

Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008

J. Emerson, S. Mcnamara, J. Burns, 2010, Pediatric pulmonology.

156 – Burkholderia cepacia Complex and Other Burkholderia Species

J. Burns, 2012 .

Emergence of new pathogens in CF: the devil we know or the devil we don't know?

J. Burns, 2002, The Journal of pediatrics.

Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings

J. Emerson, R. Gibson, J. Englund, 2011, Influenza and other respiratory viruses.

157 – Stenotrophomonas maltophilia

J. Burns, 2012 .

Identification and Detection ofStenotrophomonas maltophilia by rRNA-Directed PCR

P. Whitby, J. Lipuma, T. Stull, 2000, Journal of Clinical Microbiology.

Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure.

R. Hogg, J. Burns, I. Chan, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Pseudomonas aeruginosa Syntrophy in Chronically Colonized Airways of Cystic Fibrosis Patients

M. McNutt, J. Burns, R. Kapur, 2012, Antimicrobial Agents and Chemotherapy.

Use of Random Amplified Polymorphic DNA PCR To Examine Epidemiology of Stenotrophomonas maltophilia andAchromobacter (Alcaligenes)xylosoxidans from Patients with Cystic Fibrosis

J. Burns, J. Krzewinski, J. Foster, 2001, Journal of Clinical Microbiology.

Pediatric urinary tract infection. Diagnosis, classification, and significance.

J. Krieger, J. Burns, M. Burns, 1987, Pediatric clinics of North America.

Septic arthritis of the temporomandibular joint: review of the literature and report of two cases in children.

J. Burns, D. Spach, R. Myall, 1993, International journal of oral and maxillofacial surgery.

Pseudomonas Species and Related Organisms

J. Burns, 2018 .

Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa.

S. Miller, M. Hackett, L. Guo, 1999, Science.

Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).

J. Burns, A. Griffith, K-John Cheung, 2004, The Journal of clinical investigation.

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

J. Burns, Jesse L. Gurgel, D. Macleod, 2009, The Journal of antimicrobial chemotherapy.

Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance

J. Burns, C. Goodall, J. J. Barry, 1996, Antimicrobial agents and chemotherapy.

Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

David A. D'Argenio, Samuel I. Miller, L. Hoffman, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Developing an international Pseudomonas aeruginosa reference panel

J. Klockgether, T. Coenye, S. McClean, 2013, MicrobiologyOpen.

Mechanisms of bacterial resistance.

J. Burns, 1995, Pediatric clinics of North America.

Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients

David A. D'Argenio, Samuel I. Miller, L. Hoffman, 2007, Molecular microbiology.

Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum.

Michael E. Watson, J. Burns, Arnold L. Smith, 2004, Microbiology.

LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa

L. Hoffman, J. Burns, Eric Déziel, 2016, mBio.

Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.

D. Hawkins, D. Friedman, J. Burns, 2003, Medical and pediatric oncology.

Contribution of Burkholderia cenocepacia Flagella to Infectivity and Inflammation

Joanna B. Goldberg, J. Goldberg, J. Burns, 2004, Infection and Immunity.

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

J. Emerson, R. Gibson, M. Rosenfeld, 2003, American journal of respiratory and critical care medicine.

Progress in cystic fibrosis and the CF Therapeutics Development Network

John P Clancy, J. Clancy, S. Donaldson, 2012, Thorax.

Use of Real-Time PCR with Multiple Targets To Identify Pseudomonas aeruginosa and Other Nonfermenting Gram-Negative Bacilli from Patients with Cystic Fibrosis

J. Emerson, J. Burns, X. Qin, 2003, Journal of Clinical Microbiology.

Ampicillin use in infant fever: a systematic review.

P. Cummings, J. Burns, Julie Brown, 2002, Archives of pediatrics & adolescent medicine.

Fifteen years of experience with bacterial meningitis.

J. Emerson, J. Burns, K G Dawson, 1999, The Pediatric infectious disease journal.

Cepacia-like syndrome caused by Burkholderia multivorans.

J. Burns, G. Zahariadis, M. Levy, 2003, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

Septic arthritis of the temporomandibular joint: review the literature and report of two cases in children of Pathology

J. Burns, D. Spach, R. Myall, 1993 .

In vitro activity of second and third generation cephalosporins against ampicillin susceptible and resistant haemophilus influenzae

A. Smith, J. Burns, K. Wong, 1988, Infection.

Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients.

David A. D'Argenio, Samuel I. Miller, H. Hayden, 2008, Genomics.

Nutrient Availability as a Mechanism for Selection of Antibiotic Tolerant Pseudomonas aeruginosa within the CF Airway

Samuel I. Miller, L. Hoffman, D. Stahl, 2010, PLoS pathogens.

Evaluation Of Two Phase II Blinded and Placebo-Controlled Studies Of Nebulized Liposomal Amikacin (Arikace") In The Treatment Of Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

C. Goss, J. Clancy, L. Saiman, 2010, ATS 2010.

Whole-Genome Sequence Variation among Multiple Isolates of Pseudomonas aeruginosa

Maynard V. Olson, R. Kaul, M. Olson, 2003, Journal of bacteriology.

Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

B. Ramsey, S. Rowe, J. Burns, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.

R. Gibson, F. Accurso, P. Zeitlin, 2003, American journal of respiratory and critical care medicine.

Evaluation of MicroScan Autoscan for Identification of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

L. Saiman, J. Burns, D. Larone, 2003, Journal of Clinical Microbiology.

Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis

J. Burns, M. Tonelli, M. Aitken, 2001, Thorax.

Comparison of Agar Diffusion Methodologies for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

Ronald N. Jones, L. Saiman, J. Burns, 2000, Journal of Clinical Microbiology.

Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.

Samuel I. Miller, L. Hoffman, R. Gibson, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation

D. P. Speert, A. Oliver, E. Smith, 2008, Journal of bacteriology.

Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia.

L. Joachimiak, S. Chattopadhyay, J. Burns, 2005, FEMS microbiology letters.

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.

S. Lewis, D. E. Tullis, J. Lipuma, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A permeability barrier as a mechanism of chloramphenicol resistance in Haemophilus influenzae

T. Stull, A. Smith, J. Burns, 1985, Antimicrobial Agents and Chemotherapy.

Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?

M. Rosenfeld, J. Burns, J. Krzewinski, 2001, The Journal of hospital infection.

Attenuated Virulence of a Burkholderia cepacia Type III Secretion Mutant in a Murine Model of Infection

C. Herfst, C. Mohr, M. Tomich, 2003, Infection and Immunity.

Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.

D. Hassett, B. Gaston, R. Hennigan, 2006, The Journal of clinical investigation.

Association between pulmonary function and sputum biomarkers in cystic fibrosis.

R. Kronmal, F. Accurso, B. Ramsey, 2007, American journal of respiratory and critical care medicine.

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

C. Goss, L. Saiman, L. Lands, 2010, JAMA.

Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.

David A. D'Argenio, Samuel I. Miller, S. Lory, 2003, Environmental microbiology.

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Umer Khan, Margaret Rosenfeld, Peter Hiatt, 2011, Archives of pediatrics & adolescent medicine.

MarkedPhenotypic Variability inPseudomonas cepacia Isolated fromaPatient withCystic Fibrosis

J. Burns, 1993 .

Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein

J. Burns, D. K. Clark, 1992, Antimicrobial Agents and Chemotherapy.

Staphylococcus aureus Protein A Mediates Interspecies Interactions at the Cell Surface of Pseudomonas aeruginosa

Gennifer E. Merrihew, L. Hoffman, M. MacCoss, 2016, mBio.

Cystic fibrosis–adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses

L. Hoffman, D. Houle, D. Radzioch, 2015, Science Advances.

Comparison of Biophysical and Biologic Properties of α‐Helical Enantiomeric Antimicrobial Peptides

Robert E W Hancock, C. Mant, R. Hodges, 2006, Chemical biology & drug design.

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

J. Emerson, R. Gibson, F. Accurso, 2007, Pediatric pulmonology.

Pulmonary exacerbations in CF patients with early lung disease.

C. Goss, L. Saiman, L. Lands, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

R. Kronmal, R. Gibson, M. Rosenfeld, 2012, Pediatric pulmonology.

Pseudomonas aeruginosa isolates of distinct sub-genotypes exhibit similar potential of antimicrobial resistance by drugs exposure

J. Burns, Shu-Lin Liu, Guirong Liu, 2013, Antonie van Leeuwenhoek.

Running Title: Sequence-Optimized Peptides Overcome ESKAPE Pathogens

R. Montelaro, J. Burns, B. Deslouches, 2014 .

58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection

S. Lewis, J. Lipuma, E. Tullis, 2012 .

WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial

S. Lewis, J. Lipuma, E. Tullis, 2012 .

84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial

S. Lewis, J. Lipuma, E. Tullis, 2011 .

Open‐label, follow‐on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa

C. Goss, L. Saiman, L. Lands, 2012, Pediatric pulmonology.

Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

B. Ramsey, S. Rowe, J. Burns, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Exploratory Study of the Prevalence and Clinical Significance of Tobramycin-Mediated Biofilm Induction in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

L. Hoffman, J. Burns, D. Elliott, 2010, Antimicrobial Agents and Chemotherapy.

Cystic fibrosis–adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses

L. Hoffman, D. Houle, D. Radzioch, 2015, Science Advances.

Open‐label, follow‐on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa

C. Goss, L. Saiman, L. Lands, 2012, Pediatric pulmonology.

Chloramphenicol accumulation by Haemophilus influenzae

J. Burns, A. Smith, 1987, Antimicrobial Agents and Chemotherapy.

Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.

L. Hoffman, J. Emerson, R. Gibson, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CHAPTER 10 – Resistance to Chloramphenicol and Fusidic Acid

J. Burns, Arnold L. Smith, 1984 .